Attached files
| file | filename |
|---|---|
| EX-10.18 - EXHIBIT 10.18 - Cyclacel Pharmaceuticals, Inc. | tm2012395d3_ex10-18.htm |
| EX-5.1 - EXHIBIT 5.1 - Cyclacel Pharmaceuticals, Inc. | tm2012395d4_ex5-1.htm |
| EX-4.8 - EXHIBIT 4.8 - Cyclacel Pharmaceuticals, Inc. | tm2012395d3_ex4-8.htm |
| EX-4.7 - EXHIBIT 4.7 - Cyclacel Pharmaceuticals, Inc. | tm2012395d3_ex4-7.htm |
| EX-1.1 - EXHIBIT 1.1 - Cyclacel Pharmaceuticals, Inc. | tm2012395d3_ex1-1.htm |
| S-1/A - S-1/A - Cyclacel Pharmaceuticals, Inc. | tm2012395-3_s1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Amendment No. 1 to Registration Statement No. 333-237180 on Form S-1 and related Prospectus of Cyclacel Pharmaceuticals, Inc. of our report dated March 5, 2020, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2019.
We also consent to the reference to our Firm under the caption “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ RSM US LLP
New York, New York
April 14, 2020